{"id":"arm-5-tirzepatide","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Diarrhea"},{"rate":"5%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL4297839","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Tirzepatide activates the GLP-1 receptor, mimicking the action of the incretin hormone glucagon-like peptide-1 (GLP-1) to regulate blood sugar levels.","oneSentence":"GLP-1 receptor agonist","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:54:19.824Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Obesity"}]},"trialDetails":[{"nctId":"NCT07481747","phase":"PHASE3","title":"Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"Obesity, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities","enrollment":2539},{"nctId":"NCT06162715","phase":"PHASE2, PHASE3","title":"GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial","status":"ENROLLING_BY_INVITATION","sponsor":"Vanderbilt University Medical Center","startDate":"2024-10-30","conditions":"Severe Obesity, Obesity, BMI Greater Than 30","enrollment":30},{"nctId":"NCT07228741","phase":"PHASE2","title":"Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity","status":"NOT_YET_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03","conditions":"Acute Lymphoblastic Leukemia, Obesity","enrollment":20},{"nctId":"NCT07202247","phase":"PHASE2","title":"Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-01-23","conditions":"Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":60},{"nctId":"NCT06630585","phase":"PHASE3","title":"GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"University of Bern","startDate":"2025-02-14","conditions":"Type 1 Diabetes (T1D)","enrollment":42},{"nctId":"NCT06518837","phase":"PHASE2","title":"Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2024-10-30","conditions":"Hormone Receptor-Positive Breast Cancer, HER2-Negative Breast Cancer","enrollment":40},{"nctId":"NCT07078838","phase":"PHASE2","title":"Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2026-04","conditions":"Endometrial Cancer, Endometrial Intraepithelial Neoplasia, Grade 1 Endometrial Endometrioid Carcinoma","enrollment":40},{"nctId":"NCT06648031","phase":"PHASE1","title":"Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants","status":"COMPLETED","sponsor":"Lexaria Bioscience Corp.","startDate":"2024-12-04","conditions":"Type2diabetes","enrollment":148},{"nctId":"NCT07179120","phase":"PHASE2","title":"Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2026-05-01","conditions":"Obesity-related Male Infertility","enrollment":180},{"nctId":"NCT07096908","phase":"PHASE4","title":"Tirzepatide Use in People With Obesity and Type 1 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Dasman Diabetes Institute","startDate":"2025-07-31","conditions":"Type1diabetes, Obesity","enrollment":60},{"nctId":"NCT06774079","phase":"PHASE4","title":"Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients","status":"RECRUITING","sponsor":"University of Miami","startDate":"2025-03-05","conditions":"Crohn Disease","enrollment":24},{"nctId":"NCT06918405","phase":"PHASE3","title":"Efficacy and Safety of Tirzepatide for Weight Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chittagong Medical College","startDate":"2025-01-01","conditions":"Obesity and Obesity-related Medical Conditions","enrollment":440},{"nctId":"NCT05706506","phase":"PHASE4","title":"A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-03-08","conditions":"Type 2 Diabetes, Diabetes Mellitus, Type 2","enrollment":152},{"nctId":"NCT05659368","phase":"PHASE2","title":"Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1","status":"UNKNOWN","sponsor":"Ospedale San Raffaele","startDate":"2024-01-01","conditions":"Wolfram Syndrome","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":21,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"Arm 5- Tirzepatide","genericName":"Arm 5- Tirzepatide","companyName":"Lexaria Bioscience Corp.","companyId":"lexaria-bioscience-corp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GLP-1 receptor agonist Used for Type 2 diabetes, Obesity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}